Feature

Beyond IOP: The Mood Effects of CAIs

Evidence from large US dataset suggests topical carbonic Anhydrase Inhibitors may increase depression risk in glaucoma patients

  • By

  • March 12, 2026

  • 5 min

Share

Recent research led by Felipe Medeiros and colleagues explored the association between topical carbonic anhydrase inhibitors (CAIs) and depressive symptoms in glaucoma patients. The study, leveraging data from the TriNetX network, revealed that the use of topical CAIs, such as dorzolamide, could lead to a significant increase in depression and anxiety, particularly in susceptible patients, especially those with prior mental health issues or multiple comorbidities. These findings call for heightened awareness and regular screening for neuropsychiatric symptoms among ophthalmology patients receiving CAIs.

Original Source(s)

Beyond IOP: The Mood Effects of CAIs

Evidence from large US dataset suggests topical carbonic Anhydrase Inhibitors may increase depression risk in glaucoma patients

  • March 12, 2026

  • 5 min

Related Content

Cataract Surgeons Gain a New Lens Tool

An extended depth of focus intraocular lens approved by the FDA is designed to improve visual range while maintaining contrast sensitivity in cataract surgery.

The Most Influential Conversations in Ophthalmology Aren’t on the Podium

How WhatsApp is quietly shaping clinical practice

Could Wegovy Raise Optic Nerve Risk?

A pharmacovigilance analysis of FDA adverse event reports finds the strongest ischemic optic neuropathy reporting signal with high-dose semaglutide formulations, with higher adjusted odds reported in men.